News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma appoints a Chief Medical Officer

August 17, 2017

PledPharma AB
Company Announcement

PledPharma appoints a Chief Medical Officer

Stockholm, 2017-08-17 08:00 CEST (GLOBE NEWSWIRE) -- 
PledPharma announces today that Dr. Stefan Carlsson has been appointed to the
newly created position as Chief Medical Officer & Vice President Clinical
Development. In the role, Stefan will have the overall responsibility for the
continued clinical development of the company's drug candidates PledOx® and

Stefan Carlsson joins at a time when PledPharma is preparing for the start of
the remaining clinical studies with the company's most advanced project,
PledOx®, a potentially new drug for preventing nerve damage caused by
chemotherapy treatment. In parallel, a proof of principle study with Aladote®
to prevent the occurrence of liver damage associated with paracetamol poisoning
is ongoing. 

“Stefan Carlsson has a solid scientific background with over twenty years of
experience from senior positions in the global pharmaceutical industry, where
he has been responsible for the planning and execution of several Phase III
program and contributed in bringing products to market. This has resulted in a
unique ability to design and execute clinical trial programs in a way that
meets global business requirements whilst maximizing the commercial value of
pharmaceutical projects, both in early and late stage of development," said
PledPharmas CEO Nicklas Westerholm. 

Stefan Carlsson (born 1960) has a Medical Degree and a Ph.D. in physiology from
Gothenburg University. He has long experience from leading positions in
preclinical and clinical drug development, and has published more than thirty
scientific articles, foremost in the fields of pharmacology and physiology.
Stefan joins from AstraZeneca, where he held the position as Global Clinical
Lead for several products on the market and products under development,
including Crestor® and Epanova®. Stefan begins his employment at PledPharma on
November 1, 2017. 

For more information, please contact:

Nicklas Westerholm, CEO, phone: +46 73 354 20 62

Michaela Gertz, CFO, phone: +46 709 26 17 75

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress –
a potentially debilitating and sometimes life-threatening condition that can be
caused by chemotherapy treatment and following acetaminophen (paracetamol)
overdose. The company's most advanced project PledOx® is being developed to
reduce nerve damage associated with chemotherapy. A phase IIb study has been
conducted and will serve as the basis for the continued development. The drug
candidate Aladote® is being developed to reduce the risk of acute liver failure
associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on
Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel
+46 8 463 80 00). For more information, see



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10